F-1/A: Check-Cap Pivots to AI with MBody AI Merger, Secures $30M Equity Line

Check-Cap Ltd. is undergoing a significant strategic transformation, merging with MBody AI Corp. to enter the embodied AI software market while securing a $30 million equity financing commitment.

Summary

• Check-Cap Ltd., a clinical-stage medical diagnostics company, is pivoting its business strategy following significant workforce reductions and discontinuation of calibration studies in June 2023.
• The company entered into a Merger Agreement with MBody AI Corp. on September 12, 2025, which is expected to close in the first half of 2026.
• Upon merger completion, former MBody AI equityholders are projected to own approximately 90% of the combined company's ordinary shares, with former Check-Cap equityholders owning approximately 10%.
• The combined entity will be renamed MBody AI Ltd. and will focus on developing embodied AI software platforms for autonomous systems, initially targeting the hospitality industry.
• Check-Cap's existing loans to Nobul AI Corp. will convert into a 7.5% equity position in Nobul upon the merger's closing, and the Nobul business combination agreement will be terminated without a fee.
• On December 17, 2025, Check-Cap entered into a Purchase Agreement with ARC Group International Ltd., granting the company the right to sell up to $30.0 million of its ordinary shares to ARC Group over a three-year period.
• As consideration for this commitment, Check-Cap issued 267,857 Commitment Fee Shares to ARC Group.
• This registration statement covers the resale of up to 2,267,857 ordinary shares by ARC Group, including 2,000,000 Advance Shares (at an assumed price of $1.89 per share as of January 29, 2026) and the 267,857 Commitment Fee Shares.
• Check-Cap will not receive proceeds from ARC Group's resale of shares, but may receive up to $30.0 million from direct sales to ARC Group under the Purchase Agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive development, as it provides a potential capital infusion and a strategic pivot into a high-growth AI sector, but is offset by significant shareholder dilution, past business struggles, and substantial execution risks associated with the merger and MBody AI's limited operating history.

Positives

• Potential to raise up to $30.0 million in gross proceeds through the Purchase Agreement with ARC Group International Ltd. over a three-year period, providing crucial capital.
• Strategic pivot into the rapidly growing artificial intelligence and automation market through the merger with MBody AI Corp.
• MBody AI's business model, focusing on hardware-agnostic embodied AI software platforms and an AI-as-a-Service revenue model, aligns with modern tech trends.
• MBody AI has already secured commercial arrangements with two Fortune 500 hospitality companies and other enterprise customers, indicating early market traction.
• The termination of the Nobul BCA without a termination fee and the conversion of outstanding loans into a 7.5% equity stake in Nobul represent a favorable resolution of previous commitments.

Negatives

• Existing Check-Cap shareholders face significant dilution, with their ownership expected to decrease to approximately 10% of the combined company post-merger.
• Check-Cap's legacy medical diagnostics business has been significantly scaled back, including workforce reductions and discontinuation of calibration studies, indicating past operational difficulties.
• MBody AI has a limited operating history (incorporated October 2024) and a history of operating losses, with no assurance of achieving or sustaining profitability.
• The company is not in compliance with Nasdaq's minimum $2,500,000 shareholders' equity requirement, posing a risk of delisting.
• The actual amount of proceeds from the Purchase Agreement is uncertain and dependent on market conditions and the company's discretion, potentially being less than the $30.0 million commitment.
• MBody AI's reliance on a limited number of customers and dependence on third-party vendors for hardware, integration, and maintenance introduce operational and supply chain risks.
• The timing and completion of the Merger are subject to various conditions and uncertainties, including capital availability and regulatory approvals, with no guarantee of completion.
• The company expects to incur substantial non-recurring transaction-related costs associated with the Merger.

Risks

• Inability to predict the actual number of shares sold under the Purchase Agreement or the aggregate gross proceeds, which could be substantially less than the $30.0 million commitment.
• Future sales of Ordinary Shares by the Selling Shareholder or the perception of such sales could cause the market price of Ordinary Shares to decline and be highly volatile.
• Investors purchasing shares at different times may pay different prices and experience varying levels of dilution.
• The company may require additional financing beyond the Purchase Agreement to sustain operations, and such financing may not be available on acceptable terms or at all.
• Management will have broad discretion over the use of proceeds from the Purchase Agreement, which may not necessarily improve financial condition or market value.
• Risk of being unable to maintain compliance with Nasdaq's continued listing requirements, potentially leading to delisting and reduced liquidity for Ordinary Shares.
• The issuance of Ordinary Shares in connection with the Merger will substantially dilute the relative voting power of pre-Merger Check-Cap shareholders.
• The company has incurred and expects to continue incurring substantial transaction-related costs for the Merger.
• Failure to realize the anticipated benefits of the Merger, including achieving business objectives and raising necessary capital.
• Potential for securities litigation or shareholder derivative litigation, which could divert management's attention and harm the business.
• MBody AI's limited operating history and evolving business model make it difficult to evaluate future prospects and assure sustainable growth or profitability.
• MBody AI's reliance on a limited number of enterprise customers means the loss or reduction of business from any customer could materially adversely affect results.
• Delays in development, integration challenges, or performance limitations of MBody AI's phased platform features could affect customer satisfaction and adoption.
• MBody AI's dependence on third-party vendors, integrators, and partners for hardware procurement, deployment, financing, and maintenance exposes it to procurement, integration, geopolitical, supply chain, and partner performance risks.
• Complex implementation and service delivery for MBody AI's offerings may expose it to operational risks, increased costs, and reputational harm.
• Customer adoption, expansion, and renewal of MBody AI's platform are dependent on perceived operational benefits, ROI, and customer budget cycles, which can be influenced by external factors.
• Deployment timelines and system performance for MBody AI are dependent on customer-controlled facilities and operating environments, which are outside of MBody AI's control.
• Integration with third-party software and systems for MBody AI's platform may present technical and operational challenges, increasing costs or reducing satisfaction.
• MBody AI operates in regulated environments and may be subject to evolving regulatory requirements for autonomous systems, AI, and robotics, potentially increasing costs or limiting growth.
• MBody AI has a history of operating losses and expects to continue incurring expenses, with no assurance of achieving or sustaining profitability.
• MBody AI will require additional capital to execute its business plan, and future financings may result in further dilution or restrictive covenants.
• MBody AI operates in a rapidly evolving and highly competitive market, with new technologies and competitors potentially reducing demand.
• MBody AI's future success depends on its ability to attract and retain key personnel.
• As a foreign private issuer, the combined company may follow home country corporate governance practices, potentially offering less protection to U.S. investors compared to domestic U.S. issuers.

Future Outlook

The company anticipates the merger with MBody AI Corp. to close in the first half of 2026, after which the combined entity will operate as MBody AI Ltd., focusing on developing and commercializing embodied AI software platforms. The company expects to continue advancing MBody AI's platform, leveraging its public company infrastructure, and maintaining Check-Cap's legacy assets and research activities. MBody AI's future revenues are projected to depend on the scope and duration of customer deployments, with management believing there is a significant market opportunity in labor-intensive industries for embodied AI solutions. MBody AI expects to require additional financing to fund its operations and growth initiatives and anticipates continued operating losses, with no assurance of achieving or sustaining profitability.

Management Comments

• "Our board of directors undertakes that it will not seek to make calls on or forfeit the shares offered in this offering at any time if the nominal amount per share has not been paid."
• "We also undertake to include on the agenda for our next annual general meeting of shareholders a proposal to amend our amended articles of association to re-designate the Ordinary Shares as no-par value shares, subject to applicable law and shareholder approval."

Industry Context

StockSavvy.ai notes that Check-Cap's strategic pivot from a struggling clinical-stage medical diagnostics company to an embodied AI software firm via the MBody AI merger represents a significant reorientation towards a high-growth technology sector. This move aligns with broader industry trends of increasing adoption of artificial intelligence and automation across various labor-intensive sectors like hospitality, warehousing, and healthcare. MBody AI's AI-as-a-Service business model and hardware-agnostic platform position it to capitalize on the demand for scalable and efficient autonomous systems, contrasting sharply with Check-Cap's previous challenges in medical device development.

Corporate Governance

Legal Proceedings

• Currently involved in shareholder derivative litigation relating to the Nobul BCA.
• MBody AI may face liability or compliance exposure related to the operation of autonomous systems, including claims, investigations, or regulatory scrutiny related to system performance, safety incidents, or operational failures.
• The evolving regulatory landscape for artificial intelligence, robotics, and autonomous systems could lead to new compliance obligations, restrictions, or increased regulatory oversight.

Related Party Transactions

• Upon the closing of the Merger, outstanding loans made by Check-Cap to Nobul AI Corp. will be converted into a 7.5% equity position in Nobul, and the related loan agreements will be cancelled.

Stakeholder Impact

• Shareholders: Existing Check-Cap shareholders will experience significant dilution, with their ownership decreasing to approximately 10% of the combined company post-merger. There is potential for further dilution from future sales under the Purchase Agreement. The strategic pivot to AI could offer long-term growth potential, but also carries substantial risks, including the risk of Nasdaq delisting.
• Employees: Check-Cap previously underwent significant workforce reductions. The merger implies a shift in focus to MBody AI's operations, which could impact remaining Check-Cap employees, though the filing states the legacy business will continue R&D.
• Customers: MBody AI has secured commercial arrangements with two Fortune 500 hospitality companies, indicating potential for growth and service delivery in the embodied AI market. The impact on Check-Cap's legacy medical diagnostics customers is not explicitly detailed, but the reduction in its core business suggests a diminished focus.
• Creditors: The potential to raise up to $30.0 million through the Purchase Agreement could improve the company's liquidity and ability to meet obligations, but MBody AI's history of operating losses and need for additional capital present ongoing financial risks.

Next Steps

• Consummation of the Merger with MBody AI Corp. in the first half of 2026.
• The combined company will change its name from Check-Cap Ltd. to MBody AI Ltd.
• Check-Cap's outstanding loans to Nobul AI Corp. will be converted into a 7.5% equity position in Nobul upon the merger's closing.
• The combined company intends to continue advancing MBody AI's software platform and leverage its public company infrastructure.
• Check-Cap's legacy business is expected to continue research and development activities and hold its legacy assets (patents and proprietary medical equipment).
• The company undertakes to include a proposal to amend its articles of association to re-designate Ordinary Shares as no-par value shares on the agenda for its next annual general meeting of shareholders.
• The company must regain compliance with Nasdaq's minimum shareholders' equity requirement to avoid delisting.
• The company may request advances under the Purchase Agreement once the registration statement is declared effective by the SEC.

Key Dates

Recommendation

The company is undergoing a transformative merger, pivoting from a struggling medical diagnostics business to an AI software company. While the potential for growth in the embodied AI sector is significant, the substantial dilution for existing shareholders, MBody AI's limited operating history, and the inherent execution risks of integrating two disparate businesses warrant a cautious approach. Investors should monitor the successful completion of the merger, MBody AI's customer adoption, and its path to profitability before making further investment decisions.

Keywords

Embodied AI, Artificial Intelligence, Robotics, Autonomous Systems, Software Platform, AI-as-a-Service, Merger, Equity Financing, SEC Filing, Nasdaq Listing, Medical Diagnostics, Corporate Governance, Dilution, Capital Raise